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This study evaluates the impact of breast cancer (BC) in health related quality of life (HRQL) and in 
psychological distress (PD) during the initial phases of the disease and looks for contributing factors. A 
multicentric case-control study, EpiGEICAM, was carried out. Incident BC cases and age- and residence- 
matched controls were included. Clinical, epidemiological, HRQL (SF-36) and PD information (GHQ-28) 
was collected. We used multivariable logistic regression models to estimate OR of low HRQL and of PD 
in cases compared to controls, and to identify factors associated with low HRQL and with PD. Among 
896 BC cases and 890 control women, cases had poorer scores than both, the reference population 
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and the control group, in all SF-36 scales. BC women with lower education, younger, active workers, 
never smokers, those with comorbidities, in stage IV and with surgical treatment had lower physical 
HRQL; factors associated with low mental HRQL were dissatisfaction with social support, being current 
smoker and having children. Cases had a fivefold increased odds of PD compared to controls. Managing 
comorbidities and trying to promote social support, especially in younger and less educated women, 
could improve well-being of BC patients.
Breast cancer (BC) is the second most frequently diagnosed cancer and the first among women worldwide1 and 
also in Spain2. Improvements in survival have contributed to positioning this disease as the most prevalent can-
cer3. Apart from its impact on mortality, BC entails a considerable burden secondary to the associated disability4.
Receiving a BC diagnosis can be a very distressing event in a person’s life5. Even though distress can diminish 
with time6,7, the news of this diagnosis, frequently associated with the ideas of death and suffering8, may by itself 
affect quality of life. In addition, BC patients may experience physical and psychological symptoms related to 
the disease and the treatments they receive. As a consequence, different aspects of life, including social relation-
ships or working activities may be significantly impaired. In order to assess this impact, subjective information 
provided by the patient is highly valuable, and may supplement the clinical information measured by healthcare 
professionals, resulting in a more precise assessment of patients’ health status.
Health related quality of life (HRQL) is a complex construct that attempts to reflect the impact of health 
status and health problems in the different facets of people’s life. Although research in this field has increased in 
the last years, few works have compared HRQL in BC women to that of women in the general population, and 
inconsistencies have been reported among their results9,10. It would be very useful to deepen into the knowledge 
of the HRQL in newly diagnosed BC patients and, in order to personalise physical and psychological support, 
to identify patients’ characteristics associated with worse HRQL, and to what extent these associations are also 
observed in healthy women.
Psychological distress (PD) can be understood as a reaction characterised by emotional instability, which can 
manifest itself in depression, anxiety or adjustment problems. In BC women, initial PD has been described as a 
strong predictor of distress along the follow-up11. Therefore, the identification of factors associated with higher 
PD at diagnosis could help to identify, at an early stage, women at risk for future psychological problems.
Our aim in this report is to evaluate the impact of a recent diagnosis of BC on HRQL and on PD in the Spanish 
EpiGEICAM case-control study, and the factors that modulate these effects. We will explore differences between inci-
dent BC cases and control women, as well as in comparison to the reference values for the Spanish female population.
Results
The scores for all the eight SF-36 scales and the GHQ-28 questionnaire could be calculated in 88.1% of participat-
ing BC cases (896/1017) and in 87.5% of controls (890/1017). Some differences were noted between these women 
and participants excluded due to incomplete response to the SF-36 or the GHQ-28. In both, cases and controls, 
excluded women were older, had lower education, a different regional distribution and, in those whose scores for 
specific scales could be computed, worse physical functioning than women with complete SF-36 and GHQ-28. 
Among cases, in non-respondents there was also a higher proportion of current smokers and higher satisfaction 
with social support, while there were no differences in clinicopathological characteristics. Finally, scores in the 
other HRQL scales, apart from the abovementioned physical functioning, were similar between the two groups. 
In controls, those with incomplete SF-36 or GHQ-28 were more frequently housewives or retired, postmenopau-
sal and showed worse general health, mental health, social functioning and bodily pain (Table 1).
The main characteristics of BC cases and controls included in the study are presented in Table 1. BC cases and 
controls had a similar age (mean: 50 years), more than 90% were born in Spain, more than 70% were married or 
with a partner, 20% were nulliparous, around 55% of them had no comorbidities, 41–43% were non-smokers and 
45% were caring for someone. On the other hand, BC cases reported more social support, had lower education, 
were more often retired or housewives, had lower adherence to WCRF/AICR recommendations and a higher 
frequency of BC family history (25% vs 19%).
With respect to clinical characteristics of the cases, 67% had hormone receptor positive and HER2 negative 
tumours, and 80% were in stages 0-II. At the time of answering the questionnaire, 79% had received surgery, and 
40% were receiving radiation therapy or chemotherapy (Table 1).
Psychometric properties of the questionnaires. SF-36’s internal consistency was good for the whole 
instrument and per scale. Two scales, role-physical (RP) and role-emotional (RE), showed the highest ceiling and 
floor effects; these effects were very different –even opposite- by case status (RP: ceiling/floorcontrols = 68%/11% vs. 
ceiling/floorcases = 22%/59%; RE: ceiling/floorcontrols = 76%/10% vs. ceiling/floorcases = 59%/26%). Also for social 
functioning (SF), the ceiling was more evident in controls (SF: ceiling/floorcontrols = 51%/1% vs. ceiling/floor-
cases = 26%/2%). Internal consistency of the GHQ-28 in our sample was good (Cronbach’s α = 0.913 in cases and 
0.922 in controls). Indication of a floor effect was observed, mainly among controls, with 13% of cases and 40% of 
controls scoring 0 points (Supplementary Table S1).
Health-related quality of life. In women with BC, mean scores in each of the eight SF-36 scales and in 
physical and mental component summaries were under 50, showing that these women perceived their health as 
somewhat poorer than did women in the general population. The scale with the lowest mean was role-physical 
(36.8 [95%CI:36.0;37.5]) while that with the highest mean was general health (46.9 [95%CI:46.2;47.5]) (Fig. 1). 
More than 50% of BC cases were classified as reporting low physical functioning, role-physical or social 






(N = 121) Complete (N = 896)
p value*
Incomplete 
(N = 127) Complete (N = 890)
p-value*N % N % N % N %
Sociodemographics:
Age (mean and SD) 121 52.6 (9.7) 896 50.3 (9.5) 0.013 127 53.9 (8.8) 890 49.8 (9.4) <0.001 0.415
Ethnic group
0.461 0.512 0.716   Caucasian 121 100.0% 892 99.6% 127 100.0% 887 99.7%
   Other 0 0.0% 4 0.4% 0 0.0% 3 0.3%
Country of birth
0.448 0.770 0.223
   Spain 109 90.1% 826 92.2% 116 91.3% 837 94.0%
   Other 5 4.1% 26 2.9% 3 2.4% 18 2.0%
   Missing 7 5.8% 44 4.9% 8 6.3% 35 3.9%
Region of residence
0.007 0.001 0.875
   South 51 42.1% 263 29.4% 44 34.6% 270 30.3%
   East 18 14.9% 210 23.4% 25 19.7% 206 23.1%
   Northeast 14 11.6% 119 13.3% 29 22.8% 103 11.6%
   North 16 13.2% 185 20.6% 12 9.4% 189 21.2%
   Centre 22 18.2% 119 13.3% 17 13.4% 122 13.7%
Marital status
0.162 0.467 0.622
   Married/with partner 79 65.3% 669 74.7% 95 74.8% 653 73.4%
   Divorced 14 11.6% 73 8.1% 11 8.7% 67 7.5%
   Single 14 11.6% 97 10.8% 10 7.9% 113 12.7%
   Widow 12 9.9% 55 6.1% 9 7.1% 54 6.1%
   Missing 2 1.7% 2 0.2% 2 1.6% 3 0.3%
Cohabiting
0.253 0.317 0.127
   Living with someone else 106 87.6% 807 90.1% 108 85.0% 792 89.0%
   Living alone 14 11.6% 75 8.4% 17 13.4% 94 10.6%
   Missing 1 0.8% 14 1.6% 2 1.6% 4 0.4%
Perceived social support
0.080 0.862 <0.001
   Very satisfactory 53 43.8% 408 45.5% 20 15.7% 190 21.3%
   Satisfactory 14 11.6% 226 25.2% 28 22.0% 241 27.1%
   Unsatisfactory 12 9.9% 140 15.6% 28 22.0% 209 23.5%
   Very unsatisfactory 9 7.4% 105 11.7% 29 22.8% 225 25.3%
   Missing 33 27.3% 17 1.9% 22 17.3% 25 2.8%
Education
0.004 <0.001 0.001
   No studies or primary school 36 29.8% 184 20.5% 37 29.1% 137 15.4%
   Secondary school 65 53.7% 461 51.5% 62 48.8% 442 49.7%
   University 18 14.9% 246 27.5% 26 20.5% 306 34.4%
   Missing 2 1.7% 5 0.6% 2 1.6% 5 0.6%
Socioeconomic level
0.281 0.663 0.151
   Low 25 20.7% 141 15.7% 21 16.5% 128 14.4%
   Intermediate 77 63.6% 623 69.5% 85 66.9% 616 69.2%
   High 11 9.1% 101 11.3% 15 11.8% 126 14.2%
   Missing 8 6.6% 31 3.5% 6 4.7% 20 2.2%
Working status
0.245 <0.001 0.002
   Active work (no nightshift) 71 58.7% 477 53.2% 51 40.2% 473 53.1%
   Active work (with nightshift) 1 0.8% 40 4.5% 3 2.4% 80 9.0%
   Retired 10 8.3% 57 6.4% 12 9.4% 51 5.7%
   Housewife 29 24.0% 253 28.2% 51 40.2% 216 24.3%
   Others 7 5.8% 56 6.3% 8 6.3% 60 6.7%
   Missing 3 2.5% 13 1.5% 2 1.6% 10 1.1%
Caring for someone
0.990 0.072 0.645
   No 58 47.9% 458 51.1% 76 59.8% 452 50.8%
   Yes, without severe disability 48 39.7% 369 41.2% 40 31.5% 376 42.2%
   Yes, with severe disability 5 4.1% 38 4.2% 3 2.4% 30 3.4%
   Missing 10 8.3% 31 3.5% 8 6.3% 32 3.6%
Continued






(N = 121) Complete (N = 896)
p value*
Incomplete 
(N = 127) Complete (N = 890)
p-value*N % N % N % N %
No. comorbidities
0.121 0.226 0.328
   None 60 49.6% 537 58.8% 59 46.5% 490 55.1%
   1 35 28.9% 213 23.8% 41 32.3% 227 25.5%
   2 12 9.9% 92 10.3% 19 15.0% 107 12.0%
   >2 14 11.6% 62 6.9% 8 6.3% 64 7.2%




   No psychological distress 48 39.7% 409 45.6% 80 63.0% 680 76.4%
   Psychological distress 48 39.7% 487 54.4% 35 27.6% 210 23.6%




   Never smoker 55 45.5% 389 43.4% 58 45.7% 361 40.6%
   Ex-smoker (>6 months) 19 15.7% 247 27.6% 29 22.8% 235 26.4%
   Current/Ex-smoker<6 months 43 35.5% 259 28.9% 39 30.7% 292 32.8%
   Missing 4 3.3% 1 0.1% 1 0.8% 2 0.2%
Adherence to the WCRF/AICR 
recommendations‡
 0.213 0.194 <0.001
   6–9 27 22.3% 158 17.6% 36 28.3% 229 25.7%
   4–5 64 52.9% 514 57.4% 70 55.1% 504 56.6%
   0–3 19 15.7% 191 21.3% 10 7.9% 124 13.9%
   Missing 11 9.1% 33 3.7% 11 8.7% 33 3.7%
Adherence to the WCRF/AICR 
recommendations (mean and SD) 110 5.1 (1.2) 863 4.9 (1.2) 0.074 116 5.4 (1.1) 857 5.2 (1.1) 0.144 <0.001
Hormonal factors:
Nulliparous
0.173 0.794 0.642   No 88 72.7% 701 78.2% 97 76.4% 689 77.4%
   Yes 33 27.3% 195 21.8% 30 23.6% 201 22.6%
Menopausal status
0.176 <0.001 0.288   Pre/perimenopausal 61 50.4% 510 56.9% 41 32.3% 490 55.1%
   Postmenopausal 60 49.6% 386 43.1% 86 67.7% 400 44.9%
HRT
0.407 0.185 0.714
   No 90 74.4% 753 84.0% 103 81.1% 760 85.4%
   Yes 15 12.4% 98 10.9% 18 14.2% 92 10.3%
   Missing 16 13.2% 45 5.0% 6 4.7% 38 4.3%
Benign breast pathology
0.439 0.148 0.070   No 98 81.0% 698 77.9% 110 86.6% 724 81.3%
   Yes 23 19.0% 198 22.1% 17 13.4% 166 18.7%
BC family history
0.908 0.118 0.003
   None 91 75.2% 668 74.6% 94 74.0% 723 81.2%
   Only SDR 17 14.0% 120 13.4% 16 12.6% 92 10.3%
   First degree relatives 13 10.7% 108 12.1% 17 13.4% 75 8.4%
Clinicopathological characteristics: N/A N/A N/A N/A N/A  N/A
Tumour type
0.824
   HER2-/HR + 84 69.4% 602 67.2%
   HER2 + 24 19.8% 181 20.2%
   Triple negative 13 10.7% 113 12.6%
TNM stage
0.966
   0 0 0.0% 2 0.2%
   I 41 33.9% 327 36.5%
   II 53 43.8% 384 42.9%
   III 18 14.9% 128 14.3%
   IV 4 3.3% 26 2.9%
   Missing 5 4.1% 29 3.2%
Continued
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functioning. Focusing on component summaries, 64.7% [95%CI:61.6;67.9] of cases reported low Physical 
Component Summary (PCS) compared to 30.9% [95%CI:27.9;33.9] of controls, and 37.3% [95%CI:34.1;40.4] 
of cases reported low Mental Component Summary (MCS) compared to 22.1% [95%CI:19.4;24.9] of controls. 
Results stratified by tumour stage and by treatment status are shown in Fig. 2.
These differences were maintained after adjusting for potential confounding factors. BC cases had higher odds 
of reporting low HRQL than controls in all the SF-36 scales, with ORs ranging from 2.3 [95%CI:1.8;2.9] for phys-
ical functioning to 14.0 [95%CI:10.4;18.8] for role-physical (Supplementary Fig. 1). In the analysis that differen-
tiates cases in terms of TNM stage and surgical status, differences with respect to the control group in the bodily 





(N = 121) Complete (N = 896)
p value*
Incomplete 
(N = 127) Complete (N = 890)
p-value*N % N % N % N %
Surgery
0.192
   No surgery 22 18.2% 163 18.2%
   Lumpectomy 53 43.8% 476 53.1%
   Mastectomy 39 32.2% 233 26.0%
   Missing 7 5.8% 24 2.7%
Lymphadenectomy
0.260   No 80 66.1% 637 71.1%
   Yes 41 33.9% 259 28.9%
Radiation therapy
0.861
   No 92 76.0% 688 76.8%
   Ongoing 13 10.7% 103 11.5%
   Finished 15 12.4% 97 10.8%
   Missing 1 0.8% 8 0.9%
Chemotherapy
0.213
   No 67 55.4% 489 54.6%
   Ongoing 35 28.9% 306 34.2%
   Finished 19 15.7% 97 10.8%
   Missing 0 0.0% 4 0.4%
Endocrine therapy
0.285
   No 94 77.7% 641 71.5%
   Ongoing 26 21.5% 243 27.1%
   Finished 0 0.0% 5 0.6%
   Missing 1 0.8% 7 0.8%
HRQL data: N Mean (sd) N Mean (sd) p-value N Mean (sd) N Mean (sd) p-value p-value†
Physical Functioning 94 60.8 (28.0) 896 65.4 (25.8) 0.147 107 57.0 (30.8) 890 71.5 (28.2) <0.001 <0.001
Role-Physical 68 34.4 (44.6) 896 30.4 (41.6) 0.662 83 75.2 (36.6) 890 80.5 (34.0) 0.117 <0.001
Bodily Pain 105 56.2 (27.7) 896 58.8 (27.9) 0.437 118 65.1 (27.1) 890 70.0 (24.1) 0.048 <0.001
General Health 78 60.1 (17.2) 896 58.8 (19.6) 0.604 83 63.3 (20.2) 890 69.0 (18.3) 0.013 <0.001
Vitality 88 56.4 (21.6) 896 56.5 (23.1) 0.711 101 57.8 (22.3) 890 60.9 (19.9) 0.134 <0.001
Social Functioning 105 71.5 (25.5) 896 70.3 (27.3) 0.848 120 78.9 (23.1) 890 85.4 (20.6) 0.001 <0.001
Role-Emotional 48 66.7 (41.8) 896 66.7 (43.6) 0.781 70 86.0 (31.6) 890 83.3 (33.1) 0.350 <0.001
Mental Health 87 63.9 (21.3) 896 62.4 (21.3) 0.514 100 63.7 (21.3) 890 70.8 (18.4) 0.001 <0.001
Table 1. Comparison of sociodemographic and clinical characteristics between participants with complete 
and incomplete response to the SF-36 and/or GHQ-28, and between cases and controls. BC: Breast cancer; 
BMI: Body mass index; DUFSS: Duke-UNC Functional Social Support; HER2: Human Epidermal Growth 
Factor Receptor 2; HR: Hormone receptors; HRQL: Health related quality of life; HRT: Hormone replacement 
therapy; N/A: Not applicable; SD: standard deviation; SDR: Second-degree relatives; WCRF/AICR: World 
Cancer Research Fund/American Institute for Cancer Research. * p-values estimated without including the 
missing category. † p-values corresponding to the comparisons between cases and controls with complete 
questionnaires. ‡ WCRF/AICR recommendations: 1) Be as lean as possible within the normal range of body 
weight, 2) be physically active as part of everyday life, 3) limit consumption of energy-dense foods and avoid 
sugary drinks, 4) eat mostly foods of plant origin, 5) limit intake of red meat and avoid processed meat, 6) limit 
alcoholic drinks, 7) limit consumption of salt and avoid moldy cereals or pulses, 8) aim to meet nutritional 
needs through diet alone, and 9) mothers to breastfeed. The tenth recommendation, targeted to cancer survivors 
was not included in the construction of the score of adherence, because it was not applicable to the recently 
diagnosed population included in our study. Thus, the score ranges from 0 to 9.
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higher in cases operated than in not operated. On the other hand, for role-emotional and the MCS, differences 
with respect to controls were higher in patients in the earliest tumour stages, independent of surgical status. For 
general health, vitality, social functioning and mental health, all cases showed higher odds of low scores compared 
to controls, being the magnitude of the ORs similar in the four subgroups (Fig. 3).
Factors related to HRQL. In women with BC, those older, retired, more educated, and smokers or former 
smokers had lower odds of low PCS. On the other hand, women that reported any comorbidity, those in stage 
IV and patients who had received surgery for BC treatment showed increased odds of low PCS (Table 2). These 
associations were similar among controls except for comorbidities, which showed a stronger association with low 
physical health in controls (p-interaction = 0.016). With respect to the mental component summary, BC women 
less satisfied with their social support and current smokers had higher odds of low MCS, while nulliparity was 
associated with reduced odds of low MCS. Among controls, younger women and those reporting first-degree BC 
relatives showed higher odds of low mental health (p-interaction: 0.005 and 0.019, respectively). The association 
with social support was stronger in controls than in BC cases, and smoking status and parity were not associated 
with mental health in control women. Results for specific SF-36 scales are reported in Supplementary Table S2. 
The sensitivity analyses including only non-metastatic BC patients produced similar results (data not shown).
Psychological distress. For BC women mean score in the GHQ-28 was 7.4 [95%CI:6.9;7.8], with 54.4% 
[95%CI:51.1;57.6] being classified as psychologically distressed. In controls, mean score was 3.6 [95%CI:3.2;3.9] 
and 23.6% [95%CI:20.8;26.4] were classified as psychologically distressed. After adjusting for potential confound-
ing factors, BC cases had a more than fivefold higher odds of PD than controls (OR = 5.7 [95%CI:4.3;7.5]). When 
taking into account TNM stage and surgical status, this OR was higher in magnitude for the subgroup of patients 
operated and in stages III/IV (OR = 11.9 [95% CI: 6.4; 22.1]) compared to the other groups (OR = 5.2 [95% CI: 
3.1; 8.9] for stage 0-II no operated, OR = 6.9 [95% CI: 3.7; 12.6] for stage III/IV no operated and OR = 5.5 [95% 
CI: 4.1; 7.4] for stage 0-II operated), although confidence intervals overlapped.
Factors related to psychological distress. In women with BC, lower satisfaction with social support, 
lower education, working with nightshifts and having children were related to higher odds of PD. More advanced 
tumour stage and chemotherapy were also associated with increased odds of PD (Table 2). In controls, the asso-
ciation with perceived social support was stronger than in cases, while no associations were observed with edu-
cation, working status or parity. Reporting more than two comorbidities and low adherence to the WCRF/AICR 
recommendations were related to higher odds of PD in control women.
Discussion
EpiGEICAM BC cases had lower mean scores in all the HRQL domains evaluated by the SF-36, compared with 
both population reference values and the sample of controls. Role-physical, physical functioning and social func-
tioning were the most affected domains. Psychological distress was very prevalent in BC cases, with more than 
50% classified as such by the GHQ-28.
Figure 1. SF-36 means and 95% CI of norm-based scores of EpiGEICAM BC cases and controls. Values 
under 50 represent a worse perception than the reference population and values over 50, a better perception. 
All p-values < 0.001. BC:Breast cancer; NBS:Norm-based scores; PF:Physical Functioning; RP:Role-Physical; 
BP:Bodily Pain; GH:General Health; VT:Vitality; SF:Social Functioning; RE:Role-emotional; MH:Mental 
Health; PCS:Physical Component Summary; MCS:Mental Component Summary.
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Factors associated with poorer scores in physical health were younger age, lower education, never smoking, 
active working status, comorbidities, advanced tumour stage and surgery. The association with comorbidities in 
BC cases was weaker than in controls. This could reflect a response shift among BC women after cancer diagnosis, 
leading them to give less importance to limitations derived from other chronic diseases. Factors associated with 
poorer physical health specifically in BC cases were active working and never smoking. Active workers may have a 
more physically demanding activity than retired women, putting in evidence the limitations caused by the disease 
or treatments. With respect to smoking, we hypothesise that current and former smokers might attribute some 
of their physical limitations to consequences of smoking instead of the oncological disease and consequently 
give higher scores than never smokers in these domains. For mental health, low satisfaction with social support, 
smoking, and parity were associated with lower scores in BC women, while in controls, a younger age and family 
history of BC were the factors associated with lower scores. Controls in our study were age-matched to cases, and 
Figure 2. Percentage of women with low scores in the SF-36 scales and component summaries in breast cancer 
cases stratified by tumour stage (a) and treatment (b), and in control women (EpiGEICAM study). Low scores 
defined as Norm-based scores five or more points under the Spanish reference population. The category of BC 
women with ongoing chemotherapy or radiation therapy includes women with or without endocrine therapy; 
the category of BC women with ongoing endocrine therapy includes those with only endocrine therapy, i.e. 
not ongoing chemo- or radiation- therapy. BC: Breast cancer; CT: Chemotherapy; ET: Endocrine therapy; RT: 
Radiation therapy; PF: Physical Functioning; RP: Role-Physical; BP: Bodily Pain; GH: General Health; VT: 
Vitality; SF: Social Functioning; RE: Role-emotional; MH: Mental Health; PCS: Physical Component Summary; 
MCS: Mental Component Summary.
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Figure 3. ORs of low scoresa in the eight SF-36 scales and the two summary components for breast cancer cases 
compared to control women in the EpiGEICAM study, by tumour stage and surgical status. ORs adjusted by 
age, country of birth, region of residence, marital status, perceived social support, education, working status, 
caregiving, comorbidities, smoking, adherence to the WCRF/AICR recommendations, nulliparity, and family 
history of breast cancer. Values over 1 indicate higher odds of a low score. aLow scores defined as five or more 
points under the reference population mean, i.e. ≤45 points. BC: Breast cancer; PF: Physical Functioning; RP: 
Role-Physical; BP: Bodily Pain; GH: General Health; VT: Vitality; SF: Social Functioning; RE: Role-Emotional; 
MH: Mental Health; PCS: Physical Component Summary Score; MCS: Mental Component Summary Score.
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Continued
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therefore, younger controls could have had a stronger psychological impact derived from their paired case having 
received the diagnosis at an earlier age. In contrast, for BC cases, having children seems to have a higher impact 
on mental health than age, which could reflect that women with children have additional worries related to the 
impact that her disease can have in their children.
The higher impairment in the physical areas compared to the psychological aspects observed in our results has 
been reported in other studies12–15, and could be related to the time of the HRQL measurement, which took place 
in the first months after surgery or during radiation therapy or chemotherapy in most participants.
With respect to the high prevalence of PD observed in BC cases in our study, even if it can be overestimated, as 
has been described with GHQ-28 in people with somatic diseases16,17, its magnitude and the differences observed 
with the control group support the importance of including appropriate screening and attention to psychological 
problems as part of the integral care for BC patients. Other studies that used the GHQ questionnaire to assess 
PD in BC women shortly after surgery have also reported elevated prevalences11,18. Dissatisfaction with social 
support, lower education, comorbidities, parity, advanced tumour stage and chemotherapy were the main deter-
minants of PD in our patients. Interestingly, the associations with education and parity were observed only in BC 
cases, possibly reflecting differences in coping strategies in less educated women and greater concern in patients 
with children.
Perceived social support was associated in our study with both, PD and the mental component of HRQL. It is 
worth noting that the percentage of women very satisfied with their social support was much higher among BC 
cases than among controls, which may reflect a good response from the social networks of these women facing a 
hard life event. However, there were still some 12% of patients very unsatisfied with their social support, for which 
interventions aimed at improving it could have a positive impact.
These results should be interpreted in the context of study limitations. First of all, the cross-sectional nature 
of the design implies that the temporal sequence cannot be stablished for some variables, and we cannot know 
whether a factor, such as social support is a cause and/or a consequence of the poor HRQL or the PD. However, 
perceived social support has been found to predict HRQL during follow-up in other studies, giving support to 
an interpretation of our results in terms of perceived social support preceding HRQL19,20. Secondly, even though 
women participation was high (82%), the sample was not randomly selected and therefore it cannot be considered 
representative of all the BC patients. In addition, women that did not complete the SF-36 or the GHQ question-
naires were not included in the analyses, leaving women older, less educated and with poorer scores in certain 
HRQL scales under-represented in our results. To mitigate these limitations we have provided a detailed descrip-
tion of the characteristics of women included in our study in order to facilitate the assessment of external validity. 
An additional limitation to the external validity is that, by design, women older than 70 years were not invited to 
participate in our study. Thirdly, although we were able to adjust by several variables, residual confounding could 
still affect our estimates due to unmeasured variables (e.g. concomitant stressful life events) or to insufficient dis-
criminative capacity of the variables included (e.g. comorbidities were self-reported through an open question). 
Also, the generic nature of the SF-36 may limit the possibility of evidencing certain disease- or treatment- specific 
adverse events or consequences. Nevertheless, this instrument has allowed us detecting differences with respect to 
the reference population and to the group of controls. On the other hand, given that we showed a comprehensive 
description of SF-36’s results, including the eight individual scales and the two component summaries, and that 
we did not perform multiple testing adjustments, probability of finding some spurious statistically significant 
associations could not be ruled out. In this regard, consistency with other studies may help to assess the validity of 
our findings. The differences observed in ceiling and floor effects between cases and controls may have influenced 
our results, underestimating differences between these groups. Lastly, it should be noticed that controls were 
mostly selected among in-law relatives, friends and colleagues of BC cases, and therefore, they could be affected 
by the situation of their paired case. This would contribute to underestimate the differences in HRQL between 
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N/AOngoing RT 79 0.83(0.47;1.47) 1.15(0.67;1.99) 1.08(0.63;1.85)












N/AOngoing CT 253 1.08(0.71;1.66) 1.06(0.71;1.60) 1.75(1.17;2.61)
Finished CT 76 0.98(0.51;1.91) 1.14(0.62;2.11) 2.03(1.09;3.76)
Table 2. Association of sociodemographic, lifestyle, and clinical factors with low scoresa in the SF-36 
component summaries and with psychological distress. aLow score: scores ≤45 points, i.e. five or more points 
under the reference population mean, fixed at 50 points. ORs and 95% confidence intervals derived from 
multivariable logistic regression models, adjusted by all the variables in the table and by region of residence. 
Data in bold represent statistically significant associations. *Statistically significant trend. CT: Chemotherapy; 
HER2: Human epidermal growth factor receptor 2; HR: Hormone Receptor; N/A: Not applicable; RT: Radiation 
therapy; SDR: Second-degree relatives; p-hom: p homogeneity, estimated from the model including interaction 
terms between each factor and case/control status.
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the reference population, with the exception of physical functioning (Fig. 1), we consider that the magnitude of 
this underestimation would not be very high.
The current work has also some strengths, such as the high sample size, the exhaustiveness of data collection 
and the high participation rate. Also, we used the SF-36, which has shown good performance in BC patients, 
both in the literature21,22 and in our own sample. The availability of population based reference values for this 
instrument allows a richer interpretation of the scores obtained, including an approximation to the impact of BC 
on HRQL. In addition, the recruitment of a control group also contributed to discern which limitations in HRQL 
could be more specifically derived from BC.
Results from this study contribute to characterise the impact of a recent breast cancer diagnosis in women’ 
quality of life and the factors associated with impaired HRQL and with PD. This information could aid to advise 
women newly diagnosed with BC. Clinical and sociodemographic characteristics found to be related to HRQL 
and PD, such as age, education and parity could be assessed in clinical practice in order to identify women at 
increased risk of impaired HRQL and mental status, who may need specific interventions to improve them. 
Controlling comorbidities and reinforcing perceived social support could contribute, in the context of integral 
health care, to reduce the impact of BC diagnosis on women’ quality of life. This is particularly important in less 
educated women, who have greater psychological distress.
Methods
EpiGEICAM is a case-control study carried out in nine Spanish regions. The study methods have been previously 
described23,24. Briefly, staff of the Oncology Departments of 23 public hospitals, members of the Spanish Breast 
Cancer Group (GEICAM, http://www.geicam.org/), recruited incident BC cases and controls between 2006 and 
2011. To be included, women had to be 18–70 years old, able to answer an epidemiological questionnaire, and 
give written informed consent. For cases, BC had to be histologically confirmed and diagnosed in the last three 
months before recruitment. Women with previous history of BC were excluded. Controls were mainly selected 
by each BC case among their in-law relatives, friends, coworkers, and neighbours, and were matched by age 
(+/−5 years) and place of residence in a 1:1 ratio. All the participants answered an epidemiological questionnaire. 
Health related quality of life was measured by the SF-36 (version 1), psychological distress by the GHQ-2825 and 
perceived social support by the Duke-UNC scale26–28. A more detailed description of the SF-36 and GHQ-28 
instruments and the scoring methods applied is provided in the Supplementary Information online.
The study protocol was approved by the Ethics Committees of the 23 hospitals (Fundación Instituto Valenciano 
de Oncología; Hospital Universitario Virgen del Rocío de Sevilla; Hospital Universitario Puerta del Mar de 
Cádiz; Hospital Clínico San Carlos de Madrid; Hospital Clinic de Barcelona; Hospital Clínico Universitario de 
Valencia; Fundación Hospital Alcorcón; Complejo Hospitalario de Toledo; Hospital Mutua Terrassa; Hospital 
Universitari de Bellvitge; Hospital General Universitario de Alicante; Hospital Virgen de los Lirios de Alcoy; 
Hospital Universitari de Girona Dr. Josep Trueta; Hospital Universitari Arnau de Vilanova de Lleida; Fundació 
d’Osona per a la Recerca i l’Educació Sanitáries (FORES), and by the Regional Institutional Review Boards of 
Burgos and Soria, Aragón-CEICA, Galicia, Cantabria and Jaén). The study was conducted following the princi-
ples of the Declaration of Helsinki and subsequent updates, and all the participants gave written informed consent 
to participate.
Statistical methods. Psychometric characteristics of the SF-36 and the GHQ-28 were assessed by exploring 
the pattern of missing items, floor and ceiling effects, and the internal consistency by calculating the Cronbach’s 
alpha.
As the analyses were restricted to women with information in all the SF-36 scales and in the GHQ-28, a 
comparison was made between these women and those not included in the analyses due to incomplete SF-36 or 
GHQ-28, using Chi-squared and Mann-Whitney U tests for categorical and quantitative variables, respectively. 
We performed a similar descriptive analysis of the included cases and controls.
For each SF-36 scale and component summary score, we defined a dichotomous variable classifying women 
as having low HRQL when their Norm-Based Score (NBS) was <= 45 points, that is, five or more points lower 
than the reference population’s mean, fixed at 50 points. To compare the odds of having low HRQL and of PD 
between BC cases and controls we used multivariable logistic regression models adjusted by age, country of birth, 
region of residence, marital status, perceived social support, education, working status, caregiving, number of 
comorbidities, smoking status, nulliparity, BC family history, and adherence to the World Cancer Research Fund/
American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations29. This last variable was cal-
culated following previously described methodology30. We additionally explored the presence of differences in 
the odds of low HRQL or PD between cases and controls depending on cases’ tumour stage and surgery status. 
For this purpose we reclassified cases in four groups according to the combination of TNM tumour stage (0-II vs. 
III-IV) and surgical status (operated vs. no operated), and fitted models like those mentioned above.
To identify factors associated with low HRQL and with PD, we performed separated analyses for cases and 
controls. We used multivariable logistic regression analyses to estimate odds ratios (OR) and 95% confidence 
intervals (95% CI), including the same covariates as mentioned above and, in the analysis of BC cases, also tumour 
type, TNM stage, and type of treatment received. Lastly, we explored if the observed associations differed between 
cases and controls in a statistically significant manner. For this purpose, in the multivariable logistic regression 
models we included interaction terms between each studied factor and case/control status, and tested their statis-
tical significance. To allow tumour factors to be included in these models, controls were arbitrarily assigned to the 
categories of no surgery, no radiation therapy, no chemotherapy and stage 0/I in the corresponding variables. As 
a sensitivity analysis, we applied these same models to the subgroup of non-metastatic BC women.
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